What is the Market's View on Nurix Therapeutics Inc (NRIX) Stock's Price and Volume Trends Wednesday?

Overall market sentiment has been down on Nurix Therapeutics Inc (NRIX) stock lately. NRIX receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Nurix Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on NRIX!

See Full NRIX Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With NRIX Stock Today?

Nurix Therapeutics Inc (NRIX) stock is trading at $5.48 as of 1:15 PM on Wednesday, Oct 18, a decline of -$0.60, or -9.87% from the previous closing price of $6.08. The stock has traded between $5.40 and $6.01 so far today. Volume today is below average. So far 324,480 shares have traded compared to average volume of 469,169 shares. To screen for more stocks like Nurix Therapeutics Inc click here.

More About Nurix Therapeutics Inc

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. Click Here to get the full Stock Report for Nurix Therapeutics Inc stock.